Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discu...
Saved in:
Main Authors: | Noriyuki Takai, Hisashi Narahara |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Obstetrics and Gynecology International |
Online Access: | http://dx.doi.org/10.1155/2010/923824 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acetylation and Histone Deacetylase Inhibitors in Cancer
by: Madeleine S. Q. Kortenhorst, et al.
Published: (2006-01-01) -
Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
by: Androniki Kretsovali, et al.
Published: (2012-01-01) -
Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX
by: Lynda Ekou, et al.
Published: (2011-01-01) -
Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives
by: Hua Zhang, et al.
Published: (2015-01-01) -
Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats
by: Yu Mao, et al.
Published: (2019-01-01)